Frequency of asymptomatic hyperuricemia among adults with type 1 and type 2 diabetes

Main Article Content

A.A. Cherniaieva


Background. The purpose is to study the frequency of asymptomatic hyperuricemia (HU) in patients with type 1 and 2 diabetes in the Ukrainian population on the example of residents of Kharkiv and Kharkiv region. Materials and methods. Three hundred and sixteen individuals with diabetes mellitus were examined: 81 — with type 1 diabetes (group 1), 150 — with type 2 diabetes (group 2) and 85 type 2 diabetes patients with absolute insulin dependence (group 3). Assessment of the state of purine metabolism was performed by determining the concentration of uric acid in the blood serum and urine. Uric acid levels were evaluated by colorimetric method using a set of reagents SpinLab, UricasePOD (Ukraine). To assess the impact of patient’s age, patient’s age at the time of disease onset, disease duration and body mass index, the groups were divided into two subgroups (A and B, respectively) depending on the level of uricemia and uricosuria. Subgroup 1A consisted of 60 patients with type 1 diabetes without hyperuricemia and/or hyperuricosuria (HUC), subgroup 1B — 21 people with HU and/or HUC; subgroup 2A — 76 individuals without HU and/or HUC, subgroup 2B — 74 patients with HU and/or HUC, subgroup 3A — 57 people without HU and/or HUC, subgroup 3B — 28 individuals with HU and/or HUC. Results. The frequency of purine exchange disorders among adults with type 1 and 2 diabetes in Kharkiv region is 38.9 %. The highest frequency of purine exchange disorders is observed in patients with type 2 diabetes (49.3 %). The age the of patient during the study and at the time of manifestation of diabetes mellitus, the duration of the disease and the body mass index are not determining factors that affect the formation of disorders of purine metabolism in people with type 1 and 2 diabetes; the age and duration of the disease are risk factors for violations of purine metabolism in individuals with type 2 diabetes with absolute insulin dependence. Conclusions. Asymptomatic hyperuricemia was diagnosed in 27.8 % of the examined patients with diabetes mellitus. The frequency of asymptomatic hyperuricemia is significantly higher in individuals with type 2 diabetes than in those with type 1 diabetes (3.48 and 24.4 %, respectively); absolute insulin dependence in patients with type 2 diabetes does not affect the frequency of asymptomatic hyperuricemia.

Article Details

How to Cite
Cherniaieva, A. “Frequency of Asymptomatic Hyperuricemia Among Adults With Type 1 and Type 2 Diabetes”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 4, May 2020, pp. 327-32, doi:10.22141/2224-0721.16.4.2020.208486.
Original Researches


Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102-110. doi:10.1002/acr.20344.

Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122. doi:10.1186/1471-2369-15-122.

Lv Q, Meng XF, He FF, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One. 2013;8(2):e56864. doi:10.1371/journal.pone.0056864.

FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi:10.1002/acr.24180.

Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-3141. doi:10.1002/art.30520.

Uaratanawong S, Suraamornkul S, Angkeaw S, Uaratanawong R. Prevalence of hyperuricemia in Bangkok population. Clin Rheumatol. 2011;30(7):887-893. doi:10.1007/s10067-011-1699-0.

Nagahama K, Iseki K, Inoue T, Touma T, Ikemiya Y, Takishita S. Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res. 2004;27(4):227-233. doi:10.1291/hypres.27.227.

Juraschek SP, Kovell LC, Miller ER, Gelber AC. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. PLoS One. 2013;8(2):e56546. doi:10.1371/journal.pone.0056546.

Cherniaieva AO, Mykytyuk MR, Karachentsev YuI, Kravchun NO. Assessment of cardiovascular risk in patients with primary chronic gout combined with metabolic syndrome. Mìžnarodnij endokrinologìčnij žurnal. 2019;15(4):298-303. doi:10.22141/2224-0721.15.4.2019.174815. (in Ukrainian).

Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115. doi:10.1002/art.22466.

Rho YH, Lu N, Peloquin CE, et al. Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016;75(1):91-95. doi:10.1136/annrheumdis-2014-205827.

Pan A, Teng GG, Yuan JM, Koh WP. Bidirectional Association between Diabetes and Gout: the Singapore Chinese Health Study. Sci Rep. 2016;6:25766. doi:10.1038/srep25766.

Lytvyn Y, Škrtić M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015;308(2):F77-F83. doi:10.1152/ajprenal.00555.2014.

Chen PH, Chen YW, Liu WJ, Hsu SW, Chen CH, Lee CL. Approximate Mortality Risks between Hyperuricemia and Diabetes in the United States. J Clin Med. 2019;8(12):2127. doi:10.3390/jcm8122127.

Liu J, Tao L, Zhao Z, et al. Two-Year Changes in Hyperuricemia and Risk of Diabetes: A Five-Year Prospective Cohort Study. J Diabetes Res. 2018;2018:6905720. doi:10.1155/2018/6905720.

Cherniaieva AO, Mykytyuk MR, Karachentsev YuI, Kravchun NO. State of glucose homeostasis in women with type 2 diabetes mellitus with hyperuricemia. Problems of Endocrine Pathology. 2019;(70):103-109. doi:10.21856/j-PEP.2019.4.14. (in Ukrrainian).

Shah P, Bjornstad P, Johnson RJ. Hyperuricemia as a potential risk factor for type 2 diabetes and diabetic nephropathy. J Bras Nefrol. 2016;38(4):386-387. doi:10.5935/0101-2800.20160061.

Woyesa SB, Hirigo AT, Wube TB. Hyperuricemia and metabolic syndrome in type 2 diabetes mellitus patients at Hawassa university comprehensive specialized hospital, South West Ethiopia. BMC Endocr Disord. 2017;17(1):76. doi:10.1186/s12902-017-0226-y.

Woldeamlak B, Yirdaw K, Biadgo B. Hyperuricemia and its Association with Cardiovascular Disease Risk Factors in Type Two Diabetes Mellitus Patients at the University of Gondar Hospital, Northwest Ethiopia. EJIFCC. 2019;30(3):325-339.

Agrawal NK, Kant S. Targeting inflammation in diabetes: Newer therapeutic options. World J Diabetes. 2014;5(5):697-710. doi:10.4239/wjd.v5.i5.697.

Chen W, Liu X, Ye S. Effects of metformin on blood and urine pro-inflammatory mediators in patients with type 2 diabetes. J Inflamm (Lond). 2016;13:34. doi:10.1186/s12950-016-0142-3.

Zhen H, Gui F. The role of hyperuricemia on vascular endothelium dysfunction. Biomed Rep. 2017;7(4):325-330. doi:10.3892/br.2017.966.

Kuwabara M, Kuwabara R, Niwa K, et al. Different Risk for Hypertension, Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body Mass Index in Japanese and American Subjects. Nutrients. 2018;10(8):1011. doi:10.3390/nu10081011.

Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61(2):225-232. doi:10.1002/art.24164.